Stock Evaluator: Eton Pharmaceuticals, Inc. (ETON)

Eton Pharmaceuticals, Inc. ETON

$60.85 -0.51 -0.83%
November 20, 2026 4:00:01 PM EST November 10, 2021 Volume: 562,528
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Commentary & Analysis


Financial Summary

Share Statistics ETON Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $1,755.0 $421.5 54%
Shares Out (Mil) 33.3 46.9 38%
Institutional Ownership 92.4% 82.0% 61%
Float (Mil) 22.5 49.2 30%
Beta 0.83 0.68 49%
Avg Daily Volume (000s) 767 347 65%
Price Change
(52-week)
261.8% 49.3% 99%
Growth ETON Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 6.4% na
Net Income (5yr) 30.3% (1.3%) 85%
EPS (5yr) 33.7% 15.1% 84
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (1.4%) (15.0%) 63%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 2 2 2
Current EPS $0.680 $1.775 $3.305
Month Ago EPS $0.435 $1.400 $2.550
# Rev Up 1 1 1
# Rev Down 0 2 1
Three Months Ago EPS $0.435 $1.400 $2.580
Year/Year Chg (35.8%) (1,138%) (2,442%)
Financials ETON Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $141 $275 29%
Net Income (TTM) (Mil) $50 ($11) 54%
EPS (TTM) $1.805 ($0.700) 69%
Operating Cash Flow (TTM) (Mil) $38 ($7) 44%
Net Cash Flow (TTM) (Mil) $19 $1 62%
Long-Term Debt (Q1) (Mil) $12 $6 29%
Enterprise Value (Q1) (Mil) $1,597 $331 47%
Valuation ETON Industry
Median
Percentile
(All Stocks)
P/B 20.15 2.08 97%
P/E 38.1 20.9 82%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 1.1 1.1 55%
Ratios ETON Industry
Median
Percentile
(All Stocks)
Gross Margin 71.2% 69.5% 82%
Net Margin 35.3% 3.6% 92%
ROA 38.1% (23.8%) 99%
ROE 90.6% (24.2%) 96%
Liabilities to Assets 44.7% 31.6% 36%
F-Score 7 3 82%

Passing Stock Screens

As of 11/20/2026, from a list of 60 stock screening strategies, ETON meetings the criteria of 1 screen:

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors